192
Participants
Start Date
October 23, 2020
Primary Completion Date
October 18, 2024
Study Completion Date
June 30, 2038
CT041 autologous CAR T-cell injection
Up to 3 times CT041 autologous CAR T-cell injection infusion
Physician's Choice(Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody)
Physician's choice of any BSC listed above
Beijing Cancer Hospital, Beijing
Ruijin Hospital, affiliated to Shanghai Jiaotong University, school of medicine, Shanghai
Fudan University Shanghai Cancer Center, Shanghai
Tianjin Medical University Cancer Institute and Hospital, Tianjin
Anhui Provincial Cancer Hospital, Hefei
Fujian Medical University Union Hospital, Fuzhou
Peking University Shenzhen Hospital, Shenzhen
Harbin medical university Affiliated Cancer Hospital, Harbin
Henan Tumor Hospital, Zhengzhou
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan
Nanjing Drum Tower Hospital, Nanjing
The Second Affiliated Hospital of Soochow University, Suzhou
Northern Jiangsu People's Hospital, Yangzhou
The Second Affiliated Hospital of Nanchang University, Nanchang
The First Hospital of Jilin University, Changchun
The First Hospital of China Medical University, Shenyang
Shandong Cancer Hospital, Jinan
The Affiliated Hospital of Qingdao University, Qingdao
Shanghai Zhongshan Hospital, Shanghai
Sichuan Cancer Hospital, Chengdu
West China Hospital, Sichuan University, Chengdu
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hanzhou
Lead Sponsor
Peking University Cancer Hospital & Institute
OTHER
Fudan University
OTHER
CARsgen Therapeutics Co., Ltd.
INDUSTRY